Nicox

This morning we have reported our third quarter 2024 update and first half 2024 financial results: a period of significant strategic progress for Nicox in which we have stabilized our financial situation

We are pleased to announce a major financing with Soleus Capital Management, L.P. today.  Soleus invested $16.5 million in Nicox through a combination of Royalty and Equity Financing.    “The agreements announced today allow us to effectively monetize our VYZULTA revenue stream, creating an immediate source of cash to finance the development of our lead asset, NCX 470, whilst also bringing in a new, specialist investor, investing at a premium, to accompany our future development.” said Gavin Spencer, Chief Executive Officer of Nicox.    The Company is now financed into Q3 2025 and we also expect to have the results from the Denali Phase 3 clinical trial in Q3 2025.    We look forward to announcing the launch in China of ZERVIATE by our partner OcuMension Therapeutics following the approval in September, and to the completion of recruitment in China in the Denali trial.    You can find the full Press Release here:  https://lnkd.in/dZjncNKD   #glaucoma #biotech #financing  

Nicox has entered into an exclusive research and global license option agreement with Glaukos Corporation for NCX 1728, our novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor.  “Glaukos possesses expertise in the treatment of ophthalmic disorders and has unique drug delivery capabilities which could optimize NCX 1728 for uses including reduction of intraocular pressure, neuroprotection and as a potential treatment for retinal diseases.” said Doug Hubatsch, Chief Scientific Officer of Nicox.   Glaukos will evaluate NCX 1728, at its cost, in a pre-clinical research program agreed between Nicox and Glaukos. The program will explore indications for the treatment of glaucoma, including neuroprotection, and in the treatment of retinal diseases. Glaukos has an option to license NCX 1728 on an exclusive global basis for development in these ophthalmic conditions, which can be exercised within certain specified periods, the first of which is in 12 months. Full details are in our Press Release: https://lnkd.in/dYFUkQ5u #glaucoma #biotech #businessdevelopment #partnering 

Nicox has entered into an exclusive research and global license option agreement with Glaukos Corporation for NCX 1728, our novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor.  “Glaukos possesses expertise in the treatment of ophthalmic disorders and has unique drug delivery capabilities which could optimize NCX 1728 for uses including reduction of intraocular pressure, neuroprotection and as a potential treatment for retinal diseases.” said Doug Hubatsch, Chief Scientific Officer of Nicox.   Glaukos will evaluate NCX 1728, at its cost, in a pre-clinical research program agreed between Nicox and Glaukos. The program will explore indications for the treatment of glaucoma, including neuroprotection, and in the treatment of retinal diseases. Glaukos has an option to license NCX 1728 on an exclusive global basis for development in these ophthalmic conditions, which can be exercised within certain specified periods, the first of which is in 12 months. Full details are in our Press Release: https://lnkd.in/dYFUkQ5u #glaucoma #biotech #businessdevelopment #partnering 

We congratulate our colleagues at our partner company, OcuMension Therapeutics, on obtaining approval for ZERVIATE for allergic conjunctivitis in China. ZERVIATE is licensed to Ocumension for the Chinese and the majority of the Southeast Asian markets, and its launch will bring another revenue stream to Nicox. #productapproval #allergy #partnership You can read the full Press Release here: https://lnkd.in/dXcZnEpy

The Board of Directors of Nicox has appointed Christine Placet, a deeply experienced CEO and financial leader in the biotech industry, as a new Board member. The Board expresses its gratitude to Michele Garufi, Co-Founder of Nicox, who is stepping down as a Board member, after nearly 30 years of dedicated and unstinting service to the company. He had served as CEO and Chairman until 2022. “Christine’s expertise, strategic vision, and leadership in biotech are invaluable assets to Nicox. I look forward to working closely with her again as we continue to drive the business forward, with the focus on our de-risked compound NCX 470, moving towards topline results from the second pivotal Phase 3 trial, Denali, in H2 2025,” says Damian Marron, Chair of Nicox Board of Directors. Click here for the full press release: https://lnkd.in/d4H_KBja #leadership #appointments #biotech #businessdevelopment #financing #glaucoma

The Board of Directors of Nicox has appointed Christine Placet, a deeply experienced CEO and financial leader in the biotech industry, as a new Board member. The Board expresses its gratitude to Michele Garufi, Co-Founder of Nicox, who is stepping down as a Board member, after nearly 30 years of dedicated and unstinting service to the company. He had served as CEO and Chairman until 2022. “Christine’s expertise, strategic vision, and leadership in biotech are invaluable assets to Nicox. I look forward to working closely with her again as we continue to drive the business forward, with the focus on our de-risked compound NCX 470, moving towards topline results from the second pivotal Phase 3 trial, Denali, in H2 2025,” says Damian Marron, Chair of Nicox Board of Directors. Click here for the full press release: https://lnkd.in/d4H_KBja #leadership #appointments #biotech #businessdevelopment #financing #glaucoma

The last patient in the U.S. in the Denali Phase 3 trial of NCX 470 has now been recruited and randomization – and we would like to thank our patients, the clinical sites, our internal team and our investors for their efforts and support in enabling us to reach this important milestone. The Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension and more than 95% of the total target number of patients have been randomized in this trial so far. NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont Blanc. “We will remain fully focused on NCX 470 and on continuing recruitment of patients in China to complete Denali as we move towards expected topline results in H2 2025.” said Doug Hubatsch, Chief Scientific Officer of Nicox. Click here for the full press release: https://lnkd.in/dphPUrNP #biotech #clinicaldevelopment #drugdevelopment #glaucoma #healthcare

Nicox continued to make good progress in the second quarter of 2024.   We concluded a successful equity offering, for a total amount of €3.3 million, in June, which adds to the upfront received from our licensing deal for NCX 470 with Kowa in Japan in February. The equity raise provides financing for the development of NCX 470 and extends our cash runway and benefited from the support of our longstanding Chinese partners Ocumension Therapeutics. Nicox has a lean structure which is focused on NCX 470 and completing the Denali Phase 3 trial with NCX 470, which continues to progress on schedule with principal results still expected in the second half of 2025. Our strengthened financial position allows us flexibility to continue exploring strategic options for Nicox, and to pursue business development discussions about NCX 470 or other drug candidates. Click here for the full press release: https://lnkd.in/d7bsfggg #biotech #financials #drugdevelopment #glaucoma #businessdevelopment

Nicox continued to make good progress in the second quarter of 2024.   We concluded a successful equity offering, for a total amount of €3.3 million, in June, which adds to the upfront received from our licensing deal for NCX 470 with Kowa in Japan in February. The equity raise provides financing for the development of NCX 470 and extends our cash runway and benefited from the support of our longstanding Chinese partners Ocumension Therapeutics. Nicox has a lean structure which is focused on NCX 470 and completing the Denali Phase 3 trial with NCX 470, which continues to progress on schedule with principal results still expected in the second half of 2025. Our strengthened financial position allows us flexibility to continue exploring strategic options for Nicox, and to pursue business development discussions about NCX 470 or other drug candidates. Click here for the full press release: https://lnkd.in/d7bsfggg #biotech #financials #drugdevelopment #glaucoma #businessdevelopment